AGILE THERAPEUTICS INC: Nasdaq/NYSE listing notice — Agile Therapeutics receives Nasdaq delisting notice for failing stockholder equity compliance

AGILE THERAPEUTICS INC

Nasdaq notified Agile (AGRX) on Sept 27, 2023 that it failed to comply with $2.5M equity rule extension; delisting to proceed unless appealed.
Agile intends to request a hearing before Nasdaq Hearings Panel, which will stay delisting pending outcome.
Panel may grant up to 180 additional days (until March 25, 2024) to regain compliance; no assurance of success.
Delisting could significantly reduce liquidity, market price, and ability to raise capital for the company.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AGILE THERAPEUTICS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requests an appeal, the Staff would proceed with delisting. The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the Ru

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-23-016195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.